Global Glucagon-like Peptide-1 Receptor Agonist Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 87

Published Date: 04 Jan 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Glucagon-like Peptide-1 Receptor Agonist market size was valued at USD 9071.4 million in 2022 and is forecast to a readjusted size of USD 20650 million by 2029 with a CAGR of 12.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Glucagon-like Peptide-1 Receptor Agonist market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Glucagon-like Peptide-1 Receptor Agonist market size and forecasts, in consumption value ($ Million), 2018-2029
Global Glucagon-like Peptide-1 Receptor Agonist market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Glucagon-like Peptide-1 Receptor Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Glucagon-like Peptide-1 Receptor Agonist market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Glucagon-like Peptide-1 Receptor Agonist
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Glucagon-like Peptide-1 Receptor Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Novo Nordisk, Lily, Haosoh and Sanofi and  etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Glucagon-like Peptide-1 Receptor Agonist market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Exenatide
    Liraglutide
    Lixisenatide
    Albiglutide
    Others

Market segment by Application
    Solid Tumors
    Blood-related Tumors

Market segment by players, this report covers
    GSK
    Novo Nordisk
    Lily
    Haosoh
    Sanofi
    AstraZeneca

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Glucagon-like Peptide-1 Receptor Agonist product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Glucagon-like Peptide-1 Receptor Agonist, with revenue, gross margin and global market share of Glucagon-like Peptide-1 Receptor Agonist from 2018 to 2023.
Chapter 3, the Glucagon-like Peptide-1 Receptor Agonist competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Glucagon-like Peptide-1 Receptor Agonist market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Glucagon-like Peptide-1 Receptor Agonist.
Chapter 13, to describe Glucagon-like Peptide-1 Receptor Agonist research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Glucagon-like Peptide-1 Receptor Agonist
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Glucagon-like Peptide-1 Receptor Agonist by Type
        1.3.1 Overview: Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type in 2022
        1.3.3 Exenatide
        1.3.4 Liraglutide
        1.3.5 Lixisenatide
        1.3.6 Albiglutide
        1.3.7 Others
    1.4 Global Glucagon-like Peptide-1 Receptor Agonist Market by Application
        1.4.1 Overview: Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Solid Tumors
        1.4.3 Blood-related Tumors
    1.5 Global Glucagon-like Peptide-1 Receptor Agonist Market Size & Forecast
    1.6 Global Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast by Region
        1.6.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region, (2018-2029)
        1.6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2018-2029)
        1.6.4 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2018-2029)
        1.6.6 South America Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 GSK
        2.1.1 GSK Details
        2.1.2 GSK Major Business
        2.1.3 GSK Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.1.4 GSK Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 GSK Recent Developments and Future Plans
    2.2 Novo Nordisk
        2.2.1 Novo Nordisk Details
        2.2.2 Novo Nordisk Major Business
        2.2.3 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.2.4 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Novo Nordisk Recent Developments and Future Plans
    2.3 Lily
        2.3.1 Lily Details
        2.3.2 Lily Major Business
        2.3.3 Lily Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.3.4 Lily Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Lily Recent Developments and Future Plans
    2.4 Haosoh
        2.4.1 Haosoh Details
        2.4.2 Haosoh Major Business
        2.4.3 Haosoh Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.4.4 Haosoh Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Haosoh Recent Developments and Future Plans
    2.5 Sanofi
        2.5.1 Sanofi Details
        2.5.2 Sanofi Major Business
        2.5.3 Sanofi Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.5.4 Sanofi Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Sanofi Recent Developments and Future Plans
    2.6 AstraZeneca
        2.6.1 AstraZeneca Details
        2.6.2 AstraZeneca Major Business
        2.6.3 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
        2.6.4 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 AstraZeneca Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Glucagon-like Peptide-1 Receptor Agonist Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Glucagon-like Peptide-1 Receptor Agonist by Company Revenue
        3.2.2 Top 3 Glucagon-like Peptide-1 Receptor Agonist Players Market Share in 2022
        3.2.3 Top 6 Glucagon-like Peptide-1 Receptor Agonist Players Market Share in 2022
    3.3 Glucagon-like Peptide-1 Receptor Agonist Market: Overall Company Footprint Analysis
        3.3.1 Glucagon-like Peptide-1 Receptor Agonist Market: Region Footprint
        3.3.2 Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Type Footprint
        3.3.3 Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2018-2023)
    5.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2029)
    6.2 North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2029)
    6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        6.3.1 North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2029)
        6.3.2 United States Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        6.3.3 Canada Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        6.3.4 Mexico Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2029)
    7.2 Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2029)
    7.3 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        7.3.1 Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2029)
        7.3.2 Germany Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        7.3.3 France Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        7.3.5 Russia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        7.3.6 Italy Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region
        8.3.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2018-2029)
        8.3.2 China Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        8.3.3 Japan Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        8.3.4 South Korea Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        8.3.5 India Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        8.3.7 Australia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2029)
    9.2 South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2029)
    9.3 South America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        9.3.1 South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2029)
        9.3.2 Brazil Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        9.3.3 Argentina Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country
        10.3.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2029)
        10.3.2 Turkey Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)
        10.3.4 UAE Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Glucagon-like Peptide-1 Receptor Agonist Market Drivers
    11.2 Glucagon-like Peptide-1 Receptor Agonist Market Restraints
    11.3 Glucagon-like Peptide-1 Receptor Agonist Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Glucagon-like Peptide-1 Receptor Agonist Industry Chain
    12.2 Glucagon-like Peptide-1 Receptor Agonist Upstream Analysis
    12.3 Glucagon-like Peptide-1 Receptor Agonist Midstream Analysis
    12.4 Glucagon-like Peptide-1 Receptor Agonist Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. GSK Company Information, Head Office, and Major Competitors
    Table 6. GSK Major Business
    Table 7. GSK Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 8. GSK Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. GSK Recent Developments and Future Plans
    Table 10. Novo Nordisk Company Information, Head Office, and Major Competitors
    Table 11. Novo Nordisk Major Business
    Table 12. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 13. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Novo Nordisk Recent Developments and Future Plans
    Table 15. Lily Company Information, Head Office, and Major Competitors
    Table 16. Lily Major Business
    Table 17. Lily Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 18. Lily Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Lily Recent Developments and Future Plans
    Table 20. Haosoh Company Information, Head Office, and Major Competitors
    Table 21. Haosoh Major Business
    Table 22. Haosoh Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 23. Haosoh Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Haosoh Recent Developments and Future Plans
    Table 25. Sanofi Company Information, Head Office, and Major Competitors
    Table 26. Sanofi Major Business
    Table 27. Sanofi Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 28. Sanofi Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Sanofi Recent Developments and Future Plans
    Table 30. AstraZeneca Company Information, Head Office, and Major Competitors
    Table 31. AstraZeneca Major Business
    Table 32. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product and Solutions
    Table 33. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. AstraZeneca Recent Developments and Future Plans
    Table 35. Global Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) by Players (2018-2023)
    Table 36. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Players (2018-2023)
    Table 37. Breakdown of Glucagon-like Peptide-1 Receptor Agonist by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 38. Market Position of Players in Glucagon-like Peptide-1 Receptor Agonist, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 39. Head Office of Key Glucagon-like Peptide-1 Receptor Agonist Players
    Table 40. Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Type Footprint
    Table 41. Glucagon-like Peptide-1 Receptor Agonist Market: Company Product Application Footprint
    Table 42. Glucagon-like Peptide-1 Receptor Agonist New Market Entrants and Barriers to Market Entry
    Table 43. Glucagon-like Peptide-1 Receptor Agonist Mergers, Acquisition, Agreements, and Collaborations
    Table 44. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value (USD Million) by Type (2018-2023)
    Table 45. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Share by Type (2018-2023)
    Table 46. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Forecast by Type (2024-2029)
    Table 47. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2023)
    Table 48. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Forecast by Application (2024-2029)
    Table 49. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2023) & (USD Million)
    Table 50. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2024-2029) & (USD Million)
    Table 51. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2023) & (USD Million)
    Table 52. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2024-2029) & (USD Million)
    Table 53. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2023) & (USD Million)
    Table 54. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2024-2029) & (USD Million)
    Table 55. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2023) & (USD Million)
    Table 56. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2024-2029) & (USD Million)
    Table 57. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2023) & (USD Million)
    Table 58. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2024-2029) & (USD Million)
    Table 59. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2023) & (USD Million)
    Table 60. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2024-2029) & (USD Million)
    Table 61. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2023) & (USD Million)
    Table 62. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2024-2029) & (USD Million)
    Table 63. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2023) & (USD Million)
    Table 64. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2024-2029) & (USD Million)
    Table 65. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2018-2023) & (USD Million)
    Table 66. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Region (2024-2029) & (USD Million)
    Table 67. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2023) & (USD Million)
    Table 68. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2024-2029) & (USD Million)
    Table 69. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2023) & (USD Million)
    Table 70. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2024-2029) & (USD Million)
    Table 71. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2023) & (USD Million)
    Table 72. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2024-2029) & (USD Million)
    Table 73. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2018-2023) & (USD Million)
    Table 74. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type (2024-2029) & (USD Million)
    Table 75. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2018-2023) & (USD Million)
    Table 76. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Application (2024-2029) & (USD Million)
    Table 77. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2018-2023) & (USD Million)
    Table 78. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Country (2024-2029) & (USD Million)
    Table 79. Glucagon-like Peptide-1 Receptor Agonist Raw Material
    Table 80. Key Suppliers of Glucagon-like Peptide-1 Receptor Agonist Raw Materials
List of Figures
    Figure 1. Glucagon-like Peptide-1 Receptor Agonist Picture
    Figure 2. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type in 2022
    Figure 4. Exenatide
    Figure 5. Liraglutide
    Figure 6. Lixisenatide
    Figure 7. Albiglutide
    Figure 8. Others
    Figure 9. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 10. Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application in 2022
    Figure 11. Solid Tumors Picture
    Figure 12. Blood-related Tumors Picture
    Figure 13. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Market Glucagon-like Peptide-1 Receptor Agonist Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 16. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Region (2018-2029)
    Figure 17. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Region in 2022
    Figure 18. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 20. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 21. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 22. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 23. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Players in 2022
    Figure 24. Glucagon-like Peptide-1 Receptor Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 25. Global Top 3 Players Glucagon-like Peptide-1 Receptor Agonist Market Share in 2022
    Figure 26. Global Top 6 Players Glucagon-like Peptide-1 Receptor Agonist Market Share in 2022
    Figure 27. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Share by Type (2018-2023)
    Figure 28. Global Glucagon-like Peptide-1 Receptor Agonist Market Share Forecast by Type (2024-2029)
    Figure 29. Global Glucagon-like Peptide-1 Receptor Agonist Consumption Value Share by Application (2018-2023)
    Figure 30. Global Glucagon-like Peptide-1 Receptor Agonist Market Share Forecast by Application (2024-2029)
    Figure 31. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2018-2029)
    Figure 32. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2018-2029)
    Figure 33. North America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2018-2029)
    Figure 34. United States Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 35. Canada Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 36. Mexico Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 37. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2018-2029)
    Figure 38. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2018-2029)
    Figure 39. Europe Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2018-2029)
    Figure 40. Germany Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 41. France Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 42. United Kingdom Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 43. Russia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 44. Italy Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 45. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2018-2029)
    Figure 46. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2018-2029)
    Figure 47. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Region (2018-2029)
    Figure 48. China Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 49. Japan Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 50. South Korea Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 51. India Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 52. Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 53. Australia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 54. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2018-2029)
    Figure 55. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2018-2029)
    Figure 56. South America Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2018-2029)
    Figure 57. Brazil Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 58. Argentina Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 59. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Type (2018-2029)
    Figure 60. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Application (2018-2029)
    Figure 61. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Consumption Value Market Share by Country (2018-2029)
    Figure 62. Turkey Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 63. Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 64. UAE Glucagon-like Peptide-1 Receptor Agonist Consumption Value (2018-2029) & (USD Million)
    Figure 65. Glucagon-like Peptide-1 Receptor Agonist Market Drivers
    Figure 66. Glucagon-like Peptide-1 Receptor Agonist Market Restraints
    Figure 67. Glucagon-like Peptide-1 Receptor Agonist Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of Glucagon-like Peptide-1 Receptor Agonist in 2022
    Figure 70. Manufacturing Process Analysis of Glucagon-like Peptide-1 Receptor Agonist
    Figure 71. Glucagon-like Peptide-1 Receptor Agonist Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

GSK
Novo Nordisk
Lily
Haosoh
Sanofi
AstraZeneca

Related Reports

Global Glucagon-like Peptide-1 Receptor Agonist Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Glucagon-like Peptide-1 Receptor Agonist Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Glucagon-like Peptide-1 Receptor Agonist market size was valued at USD 9071.4 million in 2023 and is forecast to a readjusted size of USD 20650 million by 2030 with a CAGR of 12.5% during review period.

Product Tags

Glucagon-like Peptide-1 Receptor Agonist

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>